



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

December 23, 2025

Tom Frohlich  
Chief Executive Officer  
Jade Biosciences, Inc.  
221 Crescent St., Building 23  
Suite 105  
Waltham, MA 02453

**Re: Jade Biosciences, Inc.  
Registration Statement on Form S-1  
Filed December 22, 2025  
File No. 333-292369**

Dear Tom Frohlich:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at 202-551-3635 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Anthony Gostanian, Esq.